The role of cytokines in the regulation of drug disposition: Extended functional pleiotropism?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 3, 2011, Pages 341-352

  Liptrott, Neill James ^a,b   Owen, Andrew ^b  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

cytokines; drug disposition; drug metabolising enzyme; drug transporter; immune cells

Indexed keywords

ANTIRETROVIRUS AGENT; CELL NUCLEUS RECEPTOR; CISPLATIN; CYTOCHROME P450 3A; CYTOKINE; DRUG METABOLIZING ENZYME; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; IRINOTECAN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; RECOMBINANT INTERLEUKIN 2; RITONAVIR; THEOPHYLLINE; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; XENOBIOTIC AGENT;

CELL STRAIN CACO 2; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; ENZYME ACTIVITY; GENE CONTROL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; NONHUMAN; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYTOKINES; ENZYMES; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS;

EID: 79951909902     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.553600     Document Type: Review

References (120)

1. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211-21
2. Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006;46:123-49 (Pubitemid 43271186)
3. Xia CQ, Milton MN, Gan LS. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 2007;8:341-63 (Pubitemid 46780063)
4. Thomas SA. Drug transporters relevant to HIV therapy. J HIV Ther 2004;9:92-6
5. Hider SL, Hoggard P, Khoo S, et al. Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer. Arthritis Rheum 2005;52:670; author reply 2
6. Kroetz DL. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol 2006;24:4225-7 (Pubitemid 46630778)
7. Konig SK, Herzog M, Theile D, et al. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 2010;65:2319-28
8. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92 (Pubitemid 40227997)
9. Bazzoli C, Jullien V, Le Tiec C, et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 2010;49:17-45
10. van de Kerkhof EG, de Graaf IA, Ungell AL, et al. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab Dispos 2008;36:604-13 (Pubitemid 351397987)
11. Dickinson L, Khoo S, Back DJ. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008;3:296-305 (Pubitemid 351521014)
12. Jonsson EN, Macintyre F, James I, et al. Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition. Pharm Res 2005;22:1236-46 (Pubitemid 41176027)
13. Perez-Ruixo JJ, Piotrovskij V, Zhang S, et al. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Br J Clin Pharmacol 2006;62:81-96 (Pubitemid 44195245)
14. Welage LS, Carver PL, Revankar S, et al. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21:1431-8 (Pubitemid 26066634)
15. Merry C, Mulcahy F, Lloyd J. Alpha-1-acid glycoprotein concentrations in HIV disease. Implications for treatment with protease inhibitors. AIDS 1996;10:21
16. Fellay J, Marzolini C, Decosterd L, et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005;60:865-73 (Pubitemid 40386157)
17. Slain D, Pakyz A, Israel DS, et al. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000;20:898-907 (Pubitemid 30659786)
18. van den Ouweland FA, Franssen MJ, van de Putte LB, et al. Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation. Br J Clin Pharmacol 1987;23:189-93 (Pubitemid 17113495)
19. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42 (Pubitemid 46834849)
20. Gharaee-Kermani M, Phan SH. Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr Pharm Des 2001;7:1083-103 (Pubitemid 32624434)
21. Garcia VE, Quiroga MF, Ochoa MT, et al. Signaling lymphocytic activation molecule expression and regulation in human intracellular infection correlate with Th1 cytokine patterns. J Immunol 2001;167:5719-24 (Pubitemid 33062762)
22. Becker Y. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers - a review and hypothesis. Virus Genes 2004;28:5-18 (Pubitemid 38161266)
23. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 2007;137:194S-199S (Pubitemid 46052880)
24. Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-8
25. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11 (Pubitemid 32391043)
26. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999;5:828-31 (Pubitemid 29318619)
27. Hilbert DM, Kopf M, Mock BA, et al. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995;182:243-8
28. Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 2005;1:629-40
29. Carcillo JA, Doughty L, Kofos D, et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003;29:980-4 (Pubitemid 36783172)
30. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003;10:159-65 (Pubitemid 36437822)
31. Janneh O, Jones E, Chandler B, et al. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007;60:987-93 (Pubitemid 47617744)
32. Owen A. The impact of host pharmacogenetics on antiretroviral drug disposition. Curr Infect Dis Rep 2006;8:401-8 (Pubitemid 44445715)
33. Ford J, Hoggard PG, Owen A, et al. A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods 2003;274:129-37 (Pubitemid 36263049)
34. Cauda R, Lucia MB, Ortona L, et al. A new, striking morphological alteration of P-glycoprotein expression in NK cells from AIDS patients. Immunol Lett 1998;60:19-21 (Pubitemid 28133319)
35. Lucia MB, Rutella S, Rumi C, et al. Detection of P-glycoprotein efflux activity on peripheral blood lymphocyte subsets from HIV+ patients. Eur J Histochem 1997; 41:(Suppl 2):195-6
36. Ludescher C, Pall G, Irschick EU, et al. Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br J Haematol 1998;101:722-7 (Pubitemid 28308522)
37. Aggarwal S, Tsuruo T, Gupta S. Altered expression and function of P-glycoprotein (170 kDa), encoded by the MDR 1 gene, in T cell subsets from aging humans. J Clin Immunol 1997;17:448-54 (Pubitemid 28008102)
38. Zhang J, Alston MA, Huang H, et al. Human T cell cytokine responses are dependent on multidrug resistance protein-1. Int Immunol 2006;18:485-93 (Pubitemid 43329611)
39. Oselin K, Mrozikiewicz PM, Pahkla R, et al. Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur J Haematol 2003;71:119-23 (Pubitemid 36951645)
40. Owen A, Chandler B, Bray PG, et al. Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol 2004;78:12022-9 (Pubitemid 39390786)
41. Gupta S, Gollapudi S. P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol 1993;13:289-301 (Pubitemid 23282025)
42. Kock K, Grube M, Jedlitschky G, et al. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacokinet 2007;46:449-70 (Pubitemid 46827856)
43. Bleasby K, Castle JC, Roberts CJ, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 2006;36:963-88 (Pubitemid 44844110)
44. Jung N, Lehmann C, Rubbert A, et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 2008;36:1616-23
45. Janneh O, Chandler B, Hartkoorn R, et al. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2009;64:1002-7
46. Rajagopal A, Simon SM. Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell 2003;14:3389-99 (Pubitemid 37013135)
47. Sun H, Huang Y, Frassetto L, et al. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 2004;32:1239-46 (Pubitemid 39410907)
48. Huber RD, Gao B, Sidler Pfandler MA, et al. Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol Cell Physiol 2007;292:C795-806
49. Liptrott NJ, Khoo SH, Back DJ, et al. Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. J Immunol Methods 2008;339:270-4
50. Liptrott NJ, Penny M, Bray PG, et al. The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br J Pharmacol 2009;156:497-508
51. Chandramohan A, Eapen A, Govil S, et al. Determining standard liver volume: assessment of existing formulae in Indian population. Indian J Gastroenterol 2007;26:22-5 (Pubitemid 46708797)
52. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001;11:399-415 (Pubitemid 32656581)
53. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42 (Pubitemid 26096749)
54. de Lange E. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 2004;56:1793-809 (Pubitemid 39286161)
55. Vasquez EM, Petrenko Y, Jacobssen V, et al. An assessment of P-glycoprotein expression and activity in peripheral blood lymphocytes of transplant candidates. Transplant Proc 2005;37:175-7 (Pubitemid 40459727)
56. Drach J, Gsur A, Hamilton G, et al. Involvement of p-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996;88:1747-54 (Pubitemid 26307071)
57. Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002;99:3771-9 (Pubitemid 34534550)
58. Leier I, Jedlitschky G, Buchholz U, et al. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 1994;269:27807-10 (Pubitemid 24354499)
59. Randolph GJ. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin Immunol 2001;13:267-74 (Pubitemid 32744577)
60. van de Ven R, de Jong MC, Reurs AW, et al. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J Immunol 2006;176:5191-8
61. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159-68 (Pubitemid 32324448)
62. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-34
63. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60 (Pubitemid 27417790)
64. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-19
65. Albermann N, Schmitz-Winnenthal FH, ZGraggen K, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 2005;70:949-58 (Pubitemid 41138860)
66. Fardel O, Le Vee M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opin Drug Metab Toxicol 2009;5:1469-81
67. Piquette-Miller M, Pak A, Kim H, et al. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm Res 1998;15:706-11 (Pubitemid 28275646)
68. Smolnikova VV, Voznyuk AV, Potapnev MP. Cytokine-induced differentiation and proliferation of human T lymphocytes in vitro: effects of interleukin 2 and interleukin 6. Bull Exp Biol Med 2000;129:567-70
69. Belliard AM, Tardivel S, Farinotti R, et al. Effect of hr-IL2 treatment on intestinal P-glycoprotein expression and activity in Caco-2 cells. J Pharm Pharmacol 2002;54:1103-9
70. Hosten B, Abbara C, Petit B, et al. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice. Drug Metab Dispos 2008;36:1729-35
71. Tanaka Y, Tsujimura S. [Multi-drug resistance in the treatments of autoimmune diseases]. Nihon Rinsho Meneki Gakkai Kaishi 2006;29:319-24
72. Elkahwaji J, Robin MA, Berson A, et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol 1999;57:951-4 (Pubitemid 29127109)
73. Geier A, Dietrich CG, Voigt S, et al. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 2003;38:345-54 (Pubitemid 36919855)
74. Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect 2005;18:243-9 (Pubitemid 41094927)
75. Prickett TD, Brautigan DL. Cytokine activation of p38 mitogen-activated protein kinase and apoptosis is opposed by alpha-4 targeting of protein phosphatase 2A for site-specific dephosphorylation of MEK3. Mol Cell Biol 2007;27:4217-27 (Pubitemid 46906547)
76. Leu JI, Crissey MA, Leu JP, et al. Interleukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury. Mol Cell Biol 2001;21:414-24 (Pubitemid 32037362)
77. Madonna S, Scarponi C, Sestito R, et al. The IFN-gamma-dependent suppressor of cytokine signaling 1 promoter activity is positively regulated by IFN regulatory factor-1 and Sp1 but repressed by growth factor independence-1b and Kruppel-like factor-4, and it is dysregulated in psoriatic keratinocytes. J Immunol 2010;185:2467-81
78. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 2002;168:6506-13 (Pubitemid 34620077)
79. Senn JJ, Klover PJ, Nowak IA, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002;51:3391-9 (Pubitemid 35403441)
80. Bentires-Alj M, Barbu V, Fillet M, et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003;22:90-7 (Pubitemid 36152887)
81. Vilaboa NE, Galan A, Troyano A, et al. Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J Biol Chem 2000;275:24970-6 (Pubitemid 30626605)
82. Rohlff C, Glazer RI. Regulation of the MDR1 promoter by cyclic AMP-dependent protein kinase and transcription factor Sp1. Int J Oncol 1998;12:383-6 (Pubitemid 28064865)
83. Salminen A, Huuskonen J, Ojala J, et al. Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev 2008;7:83-105 (Pubitemid 351418294)
84. Puga I, Rao A, Macian F. Targeted cleavage of signaling proteins by caspase inhibits T cell receptor signaling in anergic T cells. Immunity 2008;29:193-204
85. Vega MI, Huerta-Yepez S, Martinez-Paniagua M, et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009;15:6582-94
86. Sukhai M, Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 2000;3:268-80
87. Barancik M, Bohacova V, Kvackajova J, et al. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein- mediated multidrug resistance. Eur J Pharm Sci 2001;14:29-36 (Pubitemid 32655412)
88. Shinoda C, Maruyama M, Fujishita T, et al. Doxorubicin induces expression of multidrug resistance-associated protein in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway. Int J Cancer 2005;117:21-31 (Pubitemid 41262756)
89. Bailey-Dell KJ, Hassel B, Doyle LA, et al. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 2001;1520:234-41 (Pubitemid 32868794)
90. Yu Q, Kovacs C, Yue FY, et al. The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses. J Immunol 2004;172:6047-56 (Pubitemid 38621206)
91. Chiarini F, Del Sole M, Mongiorgi S, et al. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008;22:1106-16 (Pubitemid 351833776)
92. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003;149:1-38
93. Moshage H. Cytokines and the hepatic acute phase response. J Pathol 1997;181:257-66 (Pubitemid 27156836)
94. Hatle KM, Neveu W, Dienz O, et al. Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression. Mol Cell Biol 2007;27:2952-66
95. Chen YL, Le Vraux V, Leneveu A, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994;55:649-60 (Pubitemid 24212266)
96. Cantwell CA, Sterneck E, Johnson PF. Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol 1998;18:2108-17 (Pubitemid 28152660)
97. Matsumura K, Saito T, Takahashi Y, et al. Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol Pharmacol 2004;65:326-34 (Pubitemid 38134260)
98. Huang W, Glass CK. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler Thromb Vasc Biol 2010;30:1542-9
99. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005;94:1169-86 (Pubitemid 40904182)
100. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001;7:584-90 (Pubitemid 32448326)
101. Wang W, Prosise WW, Chen J, et al. Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability. Protein Eng Des Sel 2008;21:425-33 (Pubitemid 351882132)
102. Schote AB, Turner JD, Schiltz J, et al. Nuclear receptors in human immune cells: expression and correlations. Mol Immunol 2007;44:1436-45 (Pubitemid 44415949)
103. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003;42:1331-57 (Pubitemid 38045840)
104. Tangirala RK, Bischoff ED, Joseph SB, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 2002;99:11896-901 (Pubitemid 34994495)
105. Hevener AL, Olefsky JM, Reichart D, et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 2007;117:1658-69 (Pubitemid 46871350)
106. Chow EK, Razani B, Cheng G. Innate immune system regulation of nuclear hormone receptors in metabolic diseases. J Leukoc Biol 2007;82:187-95 (Pubitemid 47230626)
107. Zhou C, Tabb MM, Nelson EL, et al. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 2006;116:2280-9 (Pubitemid 44162338)
108. Gu X, Ke S, Liu D, et al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem 2006;281:17882-9 (Pubitemid 44035587)
109. Assenat E, Gerbal-Chaloin S, Larrey D, et al. Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology 2004;40:951-60 (Pubitemid 39288129)
110. Teng S, Piquette-Miller M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J Pharmacol Exp Ther 2005;312:841-8 (Pubitemid 40189587)
111. Guerrero JM, Pozo D, Garcia-Maurino S, et al. Nuclear receptors are involved in the enhanced IL-6 production by melatonin in U937 cells. Biol Signals Recept 2000;9:197-202 (Pubitemid 30481272)
112. Bai B, Yamamoto K, Sato H, et al. Combined effect of 25- hydroxycholesterol and IL-1beta on IL-8 production in human colon carcinoma cell line (Caco-2). Inflammation 2005;29:141-6 (Pubitemid 44897911)
113. Sunman JA, Hawke RL, LeCluyse EL, et al. Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 2004;32:359-63 (Pubitemid 38263895)
114. Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28:29-39
115. He YW, Beers C, Deftos ML, et al. Down-regulation of the orphan nuclear receptor ROR gamma t is essential for T lymphocyte maturation. J Immunol 2000;164:5668-74 (Pubitemid 30389807)
116. Gorski JC, Hall SD, Becker P, et al. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 2000;67:32-43 (Pubitemid 30078385)
117. Coste A, Dubourdeau M, Linas MD, et al. PPARgamma promotes mannose receptor gene expression in murine macrophages and contributes to the induction of this receptor by IL-13. Immunity 2003;19:329-39 (Pubitemid 37153410)
118. Mencarelli A, Migliorati M, Barbanti M, et al. Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol 2010;80:1700-7
119. Le Vee M, Jouan E, Moreau A, et al. Regulation of drug transporter mRNA expression by interferon-gamma in primary human hepatocytes. Fundam Clin Pharmacol 2010
120. Hao XR, Cao DL, Hu YW, et al. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis 2009;203:417-28